

CURRICULUM VITAE

Nadia M. Bambace, MD FRCPC
NPI #1356492672

DEMOGRAPHIC AND PERSONAL INFORMATION

Appointments

September 2022 -	Attending Physician, Speciality: Hematology Focus: Hematologic malignancies and stem cell transplantation Miami Cancer Institute at Baptist Health South Florida
January 2014-August 2022	Attending Physician, Hôpital Maisonneuve-Rosemont. Institut Universitaire d'Hématologie-Oncologie et de Thérapie Cellulaire Acute leukemia and bone marrow transplantation
January 2014-August 2022	Assistant Professor of Medicine Department of Medicine Université de Montréal, Faculté de Médecine
July 2017- August 2022	Associate Program Director, Hematology Fellowship Program Department of Medicine Université de Montréal, Faculté de Médecine

Business Address

Miami Cancer Institute
Baptist Health South Florida
8900 North Kendall Drive
Miami, FL 33176

Phone : 786-595-2018
Fax : 786-814-4425
Professional email: nadia.bambace@baptisthealth.net

Personal Contact

Cell : 305-699-5633
Personal email: nadia.m.bambace@gmail.com

Citizenship: Canada (US permanent residency)
Languages: English, French, Italian, rudimentary spanish

NADIA BAMBACE, MD, FRCPC

Date

Education

- 09/1998-06/2001 McGill University, Montreal, Canada
Bachelor of Science (Nursing)
Dean's Honor list
- 08/2001-06/2005 Université de Montréal Faculté de Médecine, Montréal, Canada
Doctor in Medicine
Dean's Honor list

Postgraduate Training

- 06/2005- 08/2008 Resident Physician,
University of Vermont, Robert Larner College of Medicine, Burlington, VT
Internal Medicine Residency Program
- 09/2008-08/2011 Fellow
University of Vermont, Robert Larner College of Medicine, Burlington, VT
Hematology-Oncology Fellowship Program
- 07/2010-07/2011 Chief Fellow
University of Vermont, Robert Larner College of Medicine, Burlington, VT
Hematology-Oncology Fellowship Program
- 11/2011-12/2013 Advanced Fellow
Université de Montréal, Faculté de Médecine, Montréal, Canada
Bone Marrow Transplantation and Cellular Therapies Fellowship

Professional Experience

- 07/2007- 08/2011 Clinical Instructor of Medicine
Department of Medicine
University of Vermont
- 01/2014- 08/2022 Assistant Professor of Medicine
Department of Medicine, Université de Montréal
- 01/2014- 08/2022 Attending hematologist, Hôpital Maisonneuve-Rosemont
Acute leukemia and bone marrow transplantation
- 11/2014- 08/2022 Scientific expert consultant (acute leukemia) for the Institut National d'Excellence
en Santé et en Services Sociaux (INESSS)
- 07/2017- 08/2022 Associate Hematology Fellowship Program Director
Faculty of Medicine
Université de Montréal

Board Certification

Certification of the FSMB-USMLE – 2005

Licentiate of the Medical College of Canada – 2005

American Board of Internal Medicine – Internal Medicine Certification
Initial Certification – October 2008

American Board of Internal Medicine – Medical Oncology Certification
Initial Certification – December 2011

American Board of Internal Medicine – Hematology Certification
Initial Certification – December 2011
Recertification obtained November 2021

Fellow of the Royal College of Physicians, Canada – Hematology
Certification – October 2011
Lifelong certification with MOC

Vermont State Medical License (060-0003338) – 2005 to 2011

Quebec Medical License (CMQ - 112060) – 2011 to present

Florida State Medical License (ME157274) – 2022 to present

Memberships and Offices in Professional Societies

2005- Present	American Heart Association
2008- Present	American Society of Hematology (ASH)
2008- 2012	American Society of Clinical Oncology (ASCO)
2008- 2011	American College of Physicians (ACP)
2008- 2012	International Society on Thrombosis and Hemostasis (ISTH)
2009- Present	American Society of Bone Marrow Transplantation (ASBMT)
2011- Present	Canadian Bone Marrow Transplantation Group (CBMTG)
2011- Present	Association des médecins hématologues et oncologues du Québec (AMHOQ)
2011- Present	Canadian Hematology Society (CHS)
2020- Present	The Canadian Leukemia Study Group (CLSG)
2020 -Present	Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
2020- Present	European Society for Blood and Marrow Transplantation (EBMT)

Honors and Awards

1996	Governor General of Canada award - Government of Canada
------	---

1998	Addison-Wesley Award, Éditeurs Addison-Wesley
2000	School of Nursing Award. McGill University School of Nursing
2001	Projet Forces Avenir, Québec Provincial Finalist
2001	McGill Alumnae Scholarship & Society Prize. McGill University School of Nursing
2001	J.W. McConnell Medal, McGill University
2005	Dean's Honor List, awarded for 90 th percentile, MD degree program, Université de Montréal
2006	Arnold P. Gold Humanism in Medicine and Excellence in Teaching Award
2007	Arnold P. Gold Humanism in Medicine and Excellence in Teaching Award
2008	American Society of Hematology Trainee Award
2008	Harriet P. Dustan Award, University of Vermont, for most-promising research
2008	Frank L. Babbott MD Memorial Award, University of Vermont, for excellence in Hematology-Oncology
2013	Prize « Les attentionnés » of the Foundation of Hôpital Maisonneuve-Rosemont

Professional Committees and Administrative service

Institutional

2008-2011	University of Vermont Medical Center, Transfusion Safety Committee
2011- 2022	Hôpital Maisonneuve-Rosemont, Bone Marrow Transplantation Program Quality and Safety Committee
2014- 2022	Université de Montréal, Hematology Fellowship program- Admissions Committee
2016- 2022	Université de Montréal, Hematology Fellowship program- Competency Committee
2019- 2022	Hôpital Maisonneuve-Rosemont Director, clinical operations and hospitalisations for BMT and cellular therapy
2024-	Miami Cancer Institute, medication exceptions committee
2025-	Baptist/Miami Cancer Institute Building Collaborative Leadership program

Extramural

2018 - Present	Member and provincial representative of the AFC Working group in Hematopoietic Stem Cell Transplantation of the Royal College of Physicians of Canada in charge of the elaboration of accreditation criteria of the specialty.
2019 - Present	Medical expert on acute leukemia for the CSEMI of the Institut National d'Excellence en Santé et en Services Sociaux (INESSS). The mandate of the Comité scientifique

d'évaluation des médicaments aux fins d'inscription (CSEMI) is to make recommendations following drug product evaluations, by critically reviewing the scientific literature and determining if medications meet the criteria under the Act respecting the Institut national d'excellence en santé et en services sociaux (INESSS).

Editorial Activities

2020- 2022 Reviewer for the Canadian Journal of Thoracic Surgery
2025 Reviewer for Transplant and Cellular Therapy Journal (TCT)

Educational Activities

Medical School and Fellowship Program

2016 - 2022 Chair, Competency Committee of the Hematology Fellowship Program, Université de Montréal. Responsible for curriculum and resident evaluations.

2017- 2022 Associate Program Director Hematology Fellowship Program
Faculty of Medicine
Université de Montréal

A) Annual Courses (Numbered Courses)

MMD 1231 Sciences hématologiques.
1st year courses to Medical Students
Small group sessions, 9-10 students; 18 hours/year
Département de médecine, Université de Montréal, 2013-2021

MMD 1231 Sciences hématologiques
Plenary course on the genetics of hematological neoplasms
250 1st year medical students
Département de médecine, Université de Montréal, January 2019-2021

MMD 3511I Stage de spécialités médicales en hématologie
5 credits rotation to 2nd and 3rd year Medical Students, 50 hours/year (equivalent to 18,75 hours of plenary courses); given annually since 2014

B) Formal teaching in plenary format

Fellows from the Hematology program

- Aplastic Anemia (2 hours/course, Q-2 years since 2016)
- Board review for the Royal College Exam (1 hours/course, Q- 6 months since 2017)

Fellows from the Internal Medicine, Intensive and Critical Care program

- Hematologic Emergencies, 1 hour/course, since 2016

Residents from the Internal Medicine program

- The ABCs of Bone Marrow Transplantation 1 hour / course, since 2014

Fellows in the Bone Marrow Transplantation Program, Université de Montréal

- Advanced concepts in Bone Marrow Transplantation : 2 hours / course, 2018
- Allogeneic transplantation for AML: 2 hours /course, annually since 2018

C) Teaching in the setting of professional activities – Bone Marrow Transplantation

- BMT fellows
- Infectious Diseases fellows
- Hematology-Oncology fellows
- Pathology fellows
- Internal Medicine Residents

Includes

- Case discussions.
- Bedside teaching.
- Supervision of clinical activity (clinic and BMT unit)

90 hours/year

- BMT Unit (IUHOTC) – 210 hours/year: 36 isolation beds (HEPA filtration)
 - Acute leukemia patients
 - Stem cell transplantation

Teaching centered around the provision of this ultraspecialized care to vulnerable patients

- BMT outpatient clinic teaching (GCH)) – 100 hours/year:
 - Daily coverage of BMT emergencies
 - New BMT consults
 - Overseeing outpatient treatment of transplant patients (autologous and allogeneic non myeloablative)
 - Donor evaluations
 - Close follow up of patients post-discharge from BMT unit
 - Close supervision of cytopheresis patients. (5 days/week when assigned), greater than 20 patients weekly

D) Teaching during the provision of Clinical Care – Immediate supervisor of fellows' clinic

Weekly:. Revision of 5-6 cases with related detailed discussions on diagnosis and management.:

50 hours/year

E) Teaching during the provision of Clinical Care – Hematology

Teaching and supervision of hematology and oncology fellows

- consults
- emergency room visits
- inpatient hospitalizations
- Outpatient visits

Consults, ER, Ward : 60 hours/year

- Residents I, II, III – Internal Medicine Program
Consults, ER, Ward : 30 hours/year
- Residents – Dermatology program, medical genetics, Infectious Diseases,
Consults, ER, Ward : 30 hours/year

A) Teaching during regular scientific activities of the department of medicine and of the hematology-oncology service of the Hôpital Maisonneuve-Rosemont, includes

- a. Staff hematologist-oncologists
- b. Fellows of the programs of hematology, oncology, and internal medicine
- c. Fellows in BMT

1. Weekly scientific meeting of the service of hematology-oncology (≈44 hours/year)
2. Weekly meeting of clinical-pathological correlation of the service of hematology (≈66 hours/year)
3. Journal Club of the BMT service (≈22 hours/year)
4. Weekly scientific meeting of the program of Bone Marrow Transplantation (≈80 hours/year)

Formal lectures to physicians, fellows, residents and medical students

2025/03/21	Diagnosis and management of transplant-associated microangiopathy (TA-TMA)
2023/10/24	Disparities in HLA: strategies to overcome this in allogeneic stem cell transplantation
2021/7/7	Outcomes of CPX-351 to treat AML in the allogeneic transplant setting
2021/3/17	Haploidentical transplant after checkpoint inhibitors
2020/01/22	Severe cytokine release syndrome after haploidentical transplantation with post-transplant cyclophosphamide
2019/9/11	Revue des guidelines pour l'alloGMO en contexte de LLA chez l'adulte
2019/05/29	Mise à jour sur le traitement de la GVHa corticorefractaire
2019/01/23	Zone grise : la LMA avec mutation FLT-3 et NPM1
2018/12/12	A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)
2018/08/29	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
2018/08/29	Lymphome primaire médiastinal
2017/08/02	La LMA réfractaire : indication d'alloGMO?
2017/02/02	Retour sur le congrès ASH 2016

2017/04/17	Checkpoint inhibitors and allogeneic transplantation
2016/10/15	Graft-vs-host-disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus and mycophenolate mofetil
2016/07/20	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease
2016/03/30	Antilymphocyte globulin for the prevention of graft-vs-host-disease
2015/11/18	Bu-CY vs BU-FLU4 : A tale of two RCTs
2015/07/22	Should we transplant AML with mutated NPM1 in CR1?
2015/02/25	Best of ASBMT
2014/07/02	Retour sur le congrès ASCO 2014
2014/06/11	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
2014/01/15	BU/CY vs CY/TBI dans le traitement de la LMA
2013/07/13	Les infections à Nocardia chez les patients allogreffés de cellules souches hématopoïétiques: une étude rétrospective cas-témoin

Education of Allied Health Care Professionals

2025/08/21	The Diagnosis and Management of Graft-vs-Host Disease
2025/02/06	AML diagnosis and management
2025/02/13	ALL diagnosis and management
2020/11/13	Le syndrome de PRES
2020/09/11	Le traitement des leucémies au 2 ^e millénaire : la fin de l'approche « one size fits all ». Présentation donnée au 13 ^e préceptorat de greffe de cellules souches hématopoïétiques de l'Hôpital Maisonneuve-Rosemont
2018/05/28	Le retrait de cathéter veineux centraux. Présentation et atelier pratique Présentation donnée aux infirmier(e)s de l'unité de l'aphérèse en hématologie de l'Hôpital Maisonneuve-Rosemont
2017/04/7	L'évaluation clinique du patient atteint de cancer. Présentation aux infirmières du programme de cancérologie et radio-oncologie de l'Hôpital Maisonneuve-Rosemont
2017/01/20	Le syndrome myélodysplasique. Présentation donnée aux médecins de famille dans le cadre des journées de formation continue de l'Hôpital Maisonneuve-Rosemont affilié à l'université de Montréal
2016/11/24	Leucémie 101. Présentation aux infirmières du programme de cancérologie de l'hôpital Maisonneuve-Rosemont

2016/09/16	Leucémie lymphoïde aiguë : principes thérapeutiques et MRD. Présentation donnée au 9 ^e préceptorat de greffe de cellules souches hématopoïétiques de l'Hôpital Maisonneuve-Rosemont
2016/06/28	La biopsie cutanée, partie I. Présentation et atelier pratique. Présentation donnée aux infirmier(e)s du programme d'oncologie hémato-oncologie de l'Hôpital Maisonneuve-Rosemont
2016/06/29	La biopsie cutanée, partie II. Présentation et atelier pratique. Présentation donnée aux infirmier(e)s du programme d'hémo-oncologie de l'Hôpital Maisonneuve-Rosemont
2015/09/25	LMA : facteurs pronostiques et approche thérapeutique. Présentation donnée au 8 ^e préceptorat de greffe de cellules souches hématopoïétiques de l'Hôpital Maisonneuve-Rosemont
2014/09/26	Infections opportunistes en greffe : le visage caché de la Nocardiose. Présentation donnée au 7 ^e préceptorat de greffe de cellules souches hématopoïétiques de l'Hôpital Maisonneuve-Rosemont
2014/11/6	The principles and practice of allogeneic transplantation. Présentation donnée au Hematology Education grand rounds de l'Université du Vermont

Clinical Research Certification

Good Clinical Practice according the International Conference of Harmonization

Division 5 of Health Canada

Cancer Therapy Evaluation Program (CTEP), National Cancer Institute (NCI)

Research Experience

Principal Investigator

10/2025-	NCA34176-357: A Phase 3 Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
01/2025 -	2024-RETRO-PHRM-002: Real-World Outcomes of Intensive Chemotherapy with Cladribine, Idarubicin, and Cytarabine (CLIA) plus Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) at a Community Cancer Center (Co-PI)
07/2023 -	2023-RETRO-BAM-001: The impact of anti-thymocyte globulin exposure (ATG) on transplant-related outcomes in Ex-vivo CD34+ selected T Cell depleted allogeneic stem cell transplant for hematologic malignancies (PI)
11/2022 -	2022-RETRO-LIN-003: Real Word experience of a FLU-TBI conditioning regimen in the setting of allogeneic stem cell transplantation for hematologic malignancies (Co-PI)
2021-2022	VBP101 A first-in-Human, Open-Label, Multicenter Study of VOR33 patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation (HMR site)- (PI)
2019- 2022	UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia (Co-PI)

2018- 2022	A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled, Multicenter Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PI)
2015-2020	A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001 ("The Chimerix CMX001 Registry") (PI)
2014-2019	Phase 3 study of the safety and efficacy of CMX001 for the prevention of Cytomegalovirus (CMV) infection in CMV-seropositive (R+) hematopoietic stem cell transplant recipients (PI)
2015-2018	Phase III study of volasertib and LDAC vs placebo and LDAC in patients with denovo AML in patients > 65 y.o unfit for induction. (Interim PI)

Co-investigator

2023	CL04-ORY-An escalation/expansion, Open label, Multicenter study of iadademstat and gilteritinib in patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+): The FRIDA Study AMC-109-Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
2023	LYT-200-A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
2023	M-2018-344-A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
2023	MTX-TCL-101-A Phase 1/2, Open-Label, First-in-Human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects with CD5+ Relapsed/ Refractory Peripheral T Cell Lymphoma.
2022	VBP101-A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
2022	VBP301-Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T-Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
2022	2019-KOE-001-A Phase II Trial of CD34+ Enriched Transplants from HLA-Compatible Related or Unrelated Donors for Treatment of Patients with Hematologic Malignancies
2022	2019-KOE-003-A Pilot Study of Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients with FLT3 Mutated Acute Myeloid Leukemia followed by Consolidation with a CD34+-selected Allograft
2022	2019-KOE-004-A Phase I Dose Escalation Trial of T-cell Receptor a/B Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients with Lymphoid, Myeloid or Plasma Cell Malignancies
2022	C1071017-Elranatamab (PF-06863135) Monotherapy Expanded Access Protocol for Treatment of Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug And One ANTI-CD38 Antibody and have no Access To Other Comparable/Alternative Therapy
2020	Ponatinib-3001: A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
2019	A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant.

- 2018 ASTRAL-2A: Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3 Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD), PAREXEL Number 232011

- 2018 ALC.4/ECOG 1912 :A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.

- 2018 M16-043: Phase III Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

- 2018 Expanded Treatment Protocol (ETP) of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) who are eligible for standard induction and consolidation chemotherapy

- 2018 A phase 1 and 2 open-label study using reduced-intensity allogeneic transplant with UM171 treated cord blood in a fed-batch culture system for patients with multiple myeloma at high risk of relapse

- 2017 A phase II, open-label study of Lenalidomide and Dexamethasone followed by donor lymphocyte infusions in relapsed multiple myeloma following allogeneic stem cell transplant.

- 2017 A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation

- 2017 Phase III study of ASP 2215 vs salvage chemotherapy in patients with relapsed AML with FLT-3 mutation.

- 2017 Randomized phase II study of ribavirin, vismodegib +/- decitabine in relapsed-refractory FAB M4-M5 AML

- 2016 A phase I-II open-label study of UM171 expanded cord blood in a fed-batch culture system (UFCB-001) in patients who need an allogeneic hematopoietic stem cell transplant but lack a suitable donor.

Publications

Bibliography

1. Cohen S, Labopin M, **Bambace N**, Ahmad I, Dumont-Lagacé M, Ciceri F, McLornan DP, Labussière-Wallet H, Kröger N, de Latour RP, Chalandon Y, Forcade E, Cluzeau T, Jindra P, Kulagin A, Roy J, Lachance S, Barabé F, Caudrelier P, Sauvageau G, Yakoub-Agha I, Mohty M. Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT Registry. *Transplant Cell Ther.* 2025 Aug 14:S2666-6367(25)01365-X. doi: 10.1016/j.jtct.2025.08.006. Epub ahead of print. PMID: 40818826.
2. Castonguay M, Roy J, Claveau JS, Lachance S, Delisle JS, Kiss T, Cohen S, Fleury I, Mollica L, Ahmad I, **Bambace N**, Bernard L, Roy DC, Sauvageau G, Veilleux O. Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center. *Curr Oncol.* 2025 May 20;32(5):285. doi: 10.3390/curroncol32050285. PMID: 40422544; PMCID: PMC12109923.
3. Roy J, Cohen S, Sauvageau G, Ahmad I, Fournier V, Terra R, Caudrelier P, Thiant S, Thauvette G, **Bambace N**, Delisle JS, Lachance S, Kiss T, Bernard L, Roy DC, Veilleux O, LeBlanc R. A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients. *Transplant Cell Ther.* 2025 Jan; 31(1):34.e1-34. PMID: 39419177
4. LeBlanc R, Thiant S, Terra R, Ahmad I, Claveau JS, **Bambace N**, Bernard L, Cohen S, Delisle JS, Lachance S, Kiss T, Roy DC, Sauvageau G, Roy J. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant. *Curr Oncol.* 2024 Nov 16;31(11):7258-7274. PMID: 39590165
5. Cohen S, **Bambace N**, Ahmad I, Roy J, Tang X, Zhang MJ, Burns LJ, Barabé F, Bernard L, Delisle JS, Kiss T, Lachance S, Roy DC, Veilleux O, Sauvageau G. Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real-World Evidence. *Blood Adv.* 2023 Oct 10;7(19):5717-5726. PMID: 37467030
6. Wilck M, Cornely OA, Cordonnier C, Velez JD, Ljungman P, Maertens J, Selleslag D, Mullane KM, Nabhan S, Chen Q, Dagan R, Richmond P, Daus C, Geddie K, Tamms G, Sterling T, Patel SM, Shekar T, Musey L, Buchwald UK; **V114-022 (PNEU-STEM) study group**. A phase 3 randomized, double-blind, comparator-controlled study to evaluate safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in allogeneic hematopoietic cell transplant recipients (PNEU-STEM). *Clin Infect Dis.* 2023 Oct 13;77(8):1102-1110. PMID: 37338158
7. Claveau JS, LeBlanc R, Ahmad I, Delisle JS, Cohen S, Kiss T, **Bambace NM**, Bernard L, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J. Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD. *Transplant Cell Ther.* 2023 Jan;29(1):44.e1-44. PMID: 36334654
8. Lachance S, Bourguignon A, Boisjoly JA, Bouchard P, Ahmad I, **Bambace N**, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Veilleux O, Zehr J, Chagnon M, Roy J. Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge. *Transplant Cell Ther.* 2023 Jan;29(1):34.e1-34.e7. PMID: 36243319
9. Kadri Y, Phan M, **Bambace N**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J, Ahmad I. Donor Age and Non-Relapse Mortality: Study of The

Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Curr Oncol.* 2022 Aug 22;29(8). PMID: 36005208

10. Veilleux O, Claveau JS, Alaoui H, Roy J, Ahmad I, Delisle JS, Kiss T, **Bambace NM**, Bernard L, Cohen S, Sauvageau G, Fleury I, Mollica L, Roy DC, Serroukh Y, Lachance S. Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective. *Transplant Cell Ther.* 2022 Mar;28(3):145-151. PMID: 34954149
11. LeBlanc R, Ahmad I, Terra R, Boudreault JS, Ogez D, Lamore K, Delisle JS, **Bambace N**, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Lemieux-Blanchard É, Sauvageau G, Sebag M, Roy DC, Roy J. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. *Bone Marrow Transplant.* 2022 Feb;57(2):252-260. PMID: 34845367
12. Tremblay Z, Wong A, Otis AS, Pépin MA, **Bambace N**, Soulières D, Bouchard P, Adam JP. Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series. *Eur J Haematol.* 2022 Feb;108(2):163-165. PMID: 34653270
13. Lachance S, Gomes MM, **Bambace NM**, Bittencourt H, Lepic K, Shafey M, Karpinski J, Guilcher GMT. Recognition of Hematopoietic Stem Cell Transplantation and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused Competence in Canada. *Transplant Cell Ther.* 2021 Sep;27(9):702-706. PMID: 34153503
14. Dumont-Lagacé M, Li Q, Tanguay M, Chagraoui J, Kientega T, Cardin GB, Brasey A, Trofimov A, Carli C, Ahmad I, **Bambace NM**, Bernard L, Kiss TL, Roy J, Roy DC, Lemieux S, Perreault C, Rodier F, Dufresne SF, Busque L, Lachance S, Sauvageau G, Cohen S, Delisle JS. UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections. *Transplant Cell Ther.* 2021 Jan;27(1):76.e1-76.e9. PMID: 33022376
15. LeBlanc R, Claveau JS, Ahmad I, Delisle JS, **Bambace N**, Bernard L, Cohen S, Kiss T, Lachance S, Landais S, Roy DC, Sauvageau G, Roy J. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. *Clin Transplant.* 2020 Dec; 34(12). PMID: 32981146
16. Claveau JS, Cohen S, Ahmad I, Delisle JS, Kiss T, Lachance S, Sauvageau G, Busque L, Brito RM, **Bambace N**, Bernard L, Roy DC, Roy J. Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. *Eur J Haematol.* 2020 Dec;105(6):808-811. PMID: 32749758
17. Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, Roy DC, Barabé F, Ahmad I, **Bambace N**, Bernard L, Kiss T, Bouchard P, Caudrelier P, Landais S, Larochelle F, Chagraoui J, Lehnertz B, Corneau S, Tomellini E, van Kampen JJA, Cornelissen JJ, Dumont-Lagacé M, Tanguay M, Li Q, Lemieux S, Zandstra PW, Sauvageau G. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. *Lancet Haematol.* 2020 Feb;7(2):e134-e145. PMID: 31704264
18. Lemieux C, Ahmad I, **Bambace NM**, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. *Biol Blood Marrow Transplant.* 2020 Jan;26(1):157-161. PMID: 31521818

19. Roy DC, Lachance S, Cohen S, Delisle JS, Kiss T, Sauvageau G, Busque L, Ahmad I, Bernard L, **Bambace N**, Sidi Boumédine R, Guertin MC, Rezvani K, Mielke S, Perreault C, Roy J. Allogeneic T-cell immunotherapy after haploidentical hematopoietic stem cell transplantation without severe acute graft-versus-host disease in the absence of graft-versus-host disease prophylaxis. *Br J Haematol*. 2019 Sep;186(5):754-766. PMID: 31135970
20. Lemieux C, Ahmad I, **Bambace NM**, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Roy J, Lachance S. Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. *Leukemia Research* 2019;79:75-80. PMID: 30654975
21. Claveau JS, LeBlanc R, Ahmad I, Ferreira J, Pistono AA, **Bambace N**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy J. Cerebral adenovirus endothelitis presenting as posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2017 Oct;52(10):1457-1459. PMID: 28692025
22. Holmes CE, Levis JE, Schneider DJ, **Bambace NM**, Sharma D, Lal I, Wood ME, Muss HB. Platelet phenotype changes associated with breast cancer and its treatment. *Platelets*. 2016;27:703-711. PMID: 27135253
23. Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, **Bambace N**, Bernard L, Sabry W, Roy J. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. *BMT*. 2016;51:529-535. PMID: 26691426
24. Holmes CE, **Bambace NM**, Lewis P, Calls PW, Cushman M. Effectiveness of a short course of complex lymphedema therapy (CLT) or graduated compression stocking therapy in the treatment of post-thrombotic syndrome (PTS). *Vascular Medicine*. 2014;19:42-8. PMID: 24558028
25. **Bambace NM**, Lachance, S. Severe vasospastic angina with hemodynamic compromise related to the infusion of dimethyl sulfoxide (DMSO)-cryopreserved autologous peripheral blood stem cells. *Ann Hematol*. 2013 Nov;92(11):1571-2. PMID: 23580150
26. De Guire V, Robitaille R, Tétreault N, Guérin R, Ménard C, **Bambace N**, Sapienza P. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: Promises and challenges. *Clinical Biochemistry*. 2013;46:846-60. PMID: 23562576
27. **Bambace NM**, Holmes CE. The Platelet Contribution to Cancer Progression. *Journal of Thrombosis and Haemostasis*. 2011;9:237-249. PMID: 21040448
28. **Bambace NM**, Levis JE, Holmes CE. The Effect of P2Y-Mediated Activation on VEGF and Endostatin Release from Platelets. *Platelets*. 2010;21:85-93. PMID: 20063989

Abstracts

1. Valerie Tran, Gloribel Bonilla, Caroline Mulligan, Qingyi He, Asal Pilehvari, Wen You2, Charbel El Chaer, **Nadia Bambace**, Talia Zahra, Lyle Feinstein, Ariel Perez Perez, Daniel Reed, Firas El Chaer. Area deprivation index as a predictor of survival and treatment disparities in older adults with Acute Myeloid Leukemia: A population-based Study. ASH annual meeting, December 2025 (Poster).
2. Ethan Eilo, Pharm.D., Tiba Al Sagheer, Pharm.D., BCOP, BCACP, Audra L. Andersen, Pharm.D., BCOP, Eduardo A. Guizan Corrales, Pharm.D., BCOP, Alga Ramos Morales, Pharm.D., MS, MBA, BCPS, BCOP, CSSGB, Moe Shwin, Pharm.D., BCOP, Jessica Unzaga, Pharm.D., BCOP, **Nadia Bambace, M.D.**, Talia Zahra, M.D. Real-World Outcomes of Intensive Chemotherapy with Cladribine, Idarubicin, and

Cytarabine (CLIA) plus Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia at a Community Cancer Center. HOPA Annual meeting, April 2025 (Poster).

3. Castonguay M, Claveau JS, Roy J, Cohen S, Lachance S, Ahmad I, **Bambace N**, Bernard L, Delisle JS, Kiss T, Fleury I, Mollica L, Roy DC, Sauvageau G, Veilleux O. Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center. CCOLD Annual meeting, March 2025 (Poster).
4. Sandra Cohen, **Nadia M. Bambace**, Imran Ahmad, Lea Bernard, Jean Roy, Sylvie Lachance, Jean-Sébastien Delisle, Thomas Kiss, Denis-Claude Roy, Olivier Veilleux, Guy Sauvageau. Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity. ASH annual meeting, December 2024 (Poster).
5. Sandra Cohen, **Nadia M. Bambace**, Imran Ahmad, Lea Bernard, Jean Roy, Sylvie Lachance, Jean-Sébastien Delisle, Thomas Kiss, Denis-Claude Roy, Olivier Veilleux, Guy Sauvageau. UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia. ASH annual meeting, December 2024 (Poster).
6. Sandra Cohen, Myriam Labopin, **Nadia M. Bambace**, Imran Ahmad, Maude Dumont-Lagacé, Fabio Ciceri*, Donal P McLornan, Hélène Labussière-Wallet*, Nicolaus Kröger, Regis Peffault De Latour*, Yves Chalandon, Edouard Forcade, Thomas Cluzeau, Pavel Jindra, Aleksandr Kulagin Sr., Jean Roy, Sylvie Lachance, Frederic Barabe, Pierre Caudrelier*, Ibrahim Yakoub-Agha and Mohamad Mohty. UM171 Expanded Cord Blood Transplantation Outcomes Compare Favorably to All Different Stem Cell Sources: An EBMT Registry Case-Control Analysis. ASH annual meeting, December 2023 (Oral).
7. Filippo Milano, Guy Sauvageau, Gabrielle Thauvette, Nadia M. Bambace, Lea Bernard, Imran Ahmad, Jean Roy, Laura C Roberts, Laurel Thur, Jenna B Peders, Ann Dahlberg and Sandra Cohen. Infusion of UM171-Expanded Cord Blood Led to Excellent Survival in Patients with High-Risk Leukemias: Results from Two Independent Phase II Studies. ASH annual meeting, December 2023 (Oral).
8. Guenther Koehne, Benjamin Tomlinson, Hyung C. Suh, Divya Koura, Miguel-Angel Perales, Christina Cho, **Nadia M. Bambace**, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Michael Loken, Kyle Breitschwerdt, Sritama Nath, Glen D. Raffel, Brenda W. Cooper. CD33-Deleted Hematopoietic Stem cell and Progenitor cells display normal engraftment after hematopoietic cell transplant (HCT) and tolerate post-HCT gemtuzumab ozogamicin (GO) without cytopenias. EHA annual conference, Germany, June 2023 (Poster)
9. **Nadia Bambace**, Guenther Koehne, Ariel Perez Perez, Tiba Al Sagheer, Talia Zahra, Muni B Rubens, Yuliya Linhares. Post-transplantation cyclophosphamide-based GVHD prophylaxis after FLU-TBI Myeloablative conditioning is associated with favorable outcomes in adult patients with ALL treated with contemporary induction regimens. EBMT Annual conference, Paris, April 2023 (Poster)
10. Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, **Nadia M. Bambace**, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel: Initial first-in-human results: CD33-Deleted Hematopoietic Stem cell and Progenitor cells display normal engraftment after hematopoietic cell transplant (HCT) and tolerate post-HCT gemtuzumab ozogamicin (GO) without cytopenias. EBMT annual conference, Paris, April 2023 (Poster)
11. Jean-Francois Tourigny, Jean-Sebastien Delisle, Martin Giroux, **Nadia Bambace**, Lea Bernard, Sandra Cohen, Thomas Kiss, Sylvie Lachance, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux, Jean, Roy, Imran Ahmad. Clinical outcomes after transplantation of cryopreserved or fresh peripheral blood hematopoietic cells: a single center report. EBMT annual conference, Paris, April 2023 (Poster)
12. Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, **Nadia M. Bambace**, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M.

- Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel; Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse. Tandem Transplant and Cellular therapy Annual Meeting, February 2023 (Poster)
13. Roy J, Cohen S, Sauvageau G, Terra R, Ahmad I, **Bambace N**, Bernard L, , Delisle JS, Kiss T, Lachance S, Roy DC, Veilleux O, LeBlanc R: A Pilot study of UM171 Expanded cord blood grafts for tandem auto/allogeneic stem cell transplant in high and very high-risk myeloma patients. Tandem Transplant and Cellular therapy Annual Meeting, February 2023 (Poster)
 14. Denis-Claude Roy, Jean-Sébastien Delisle, Imran Ahmad, Brian Leber, Félix Couture, Stephanie Thiant, Natasha Kekre, Radia Sidi Boumedine, Cédric Carli, Ann Brasey, **Nadia M. Bambace**, Léa Bernard, Sandra Cohen, Thomas L. Kiss, Jean Roy, Guy Sauvageau, Olivier Veilleux, Claude Perreault, Lambert Busque, Silvy Lachance: Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation. *Blood* 2022; 140 (Supplement 1): 1601–1603. ASH annual meeting December 2022 (Poster).
 15. Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, **Nadia M. Bambace**, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel; Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse. *Blood* 2022; 140 (Supplement 1): 12973–12975. ASH annual meeting December 2022 (Poster)
 16. Yasmine Kadri, Michelle Phan, **Nadia Bambace**, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas L. Kiss, Sylvia Lachance, Denis-Claude Roy, Jean Roy, Guy Sauvageau, Olivier Veilleux, Imran Ahmad; The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood* 2022; 140 (Supplement 1): 7759–7760. ASH annual meeting December 2022 (Poster)
 17. S. Cohen, J. Roy, S. Lachance, F. Barabé, A. Marinier, I. Ahmad, **N. Bambace**, L. Bernard, J.-S. Delisle, T. Kiss, D.-C. Roy, G. Sauvageau. UM171 expansion of small cord bloods provides access to safe transplantation for donorless patients with excellent longterm follow-up. EBMT, April 2022 (Oral presentation).
 18. Philippe Bouchard, Annie Brisebois-Boyer, Anne Beaudry, Jean-Francois Berthiaume, **Nadia M. Bambace**, Léa Bernard, Josee Hebert, Julie Bergeron. Efficacy, Toxicity and Cost of Venetoclax-Based Combinations for the Treatment of Acute Myeloid Leukemia: Real-World Evidence from a Canadian Academic Center. *Blood* (2021) 138 (Supplement 1): 1253. ASH annual meeting December 2021(Poster).
 19. LeBlanc R, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard E, **Bambace NM**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J. Allogeneic hematopoietic cell transplantation followed by bortezomib in multiple myeloma: final results of a prospective trial highlighting a strong prognostic role of measurable residual disease. EBMT, April 2021 (Oral presentation)

20. Boisjoly JA, Bouchard P, Cohen S, Ahmad I, **Bambace NM**, Bernard L, Delisle JS, Kiss T, Roy DC, Sauvageau G, Roy J, Lachance S. Bendamustine -based conditioning prior to autologous hematopoietic cell transplant improves outcomes in patients with relapsed-refractory non-hodgkin lymphoma. EBMT, April 2021 (Oral presentation)

21. Maude Dumont-Lagacé, Qi Li, Mégane Tanguay, MD, Jalila Chagraoui, PhD, Tibila Kientega, Guillaume Cardin, Ann Brasey, PhD, Assya Trofimov, MSc, Cédric Carli, PhD, Imran Ahmad, MD, **Nadia M. Bambace**, Léa Bernard, MD, Thomas L. Kiss, MD, Jean Roy, MD, Denis-Claude Roy, MD, Sébastien Lemieux, PhD, Claude Perreault, MD, Francis Rodier, PhD, Simon Frédéric Dufresne, MD FRCP, Lambert Busque, MD, Silvy Lachance, MD FRCP, Guy Sauvageau, MD PhD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD. UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections. ASH annual meeting, December 2020 (Poster).

22. Sandra Cohen, MD, FRCP(C)¹, Jean Roy, MD², Jean-Sébastien Delisle, MD, PhD¹, **Nadia M. Bambace, MD¹**, Imran Ahmad, MD³, Silvy Lachance, MD, FRCP⁴, Léa Bernard, MD¹, Frederic Barabe, MD⁵, Thomas L. Kiss, MD¹, Lambert Busque, MD⁶, Denis-Claude Roy, MD⁷, Filippo Milano, MD, PhD⁸ and Guy Sauvageau, MD Ph.D. UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies. ASH annual meeting, December 2019 (Poster)

23. LeBlanc R, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard E, **Bambace NM**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J. Minimal Residual Disease Evaluation Using an 8-Color Flow Cytometry Protocol Predicts Relapse in Myeloma Patients Treated with Frontline Tandem Auto-Allo Transplant Followed by Bortezomib Consolidation. CBMTG Annual Meeting, June 2018 (Poster)

24. Sandra Cohen, Jean Roy, Silvy Lachance, Anne Marinier, Jean-Sébastien Delisle, Denis-Claude Roy, Lambert Busque, Imran Ahmad, **Nadia M. Bambace**, Frederic Barabe, Léa Bernard, Thomas L. Kiss, Philippe Bouchard, Pierre Caudrelier, Fannie Larochelle, Sébastien Lemieux, Mégane Tanguay, Jalila Chagraoui, Peter W. Zandstra, Guy Sauvageau; Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival. *Blood* 2018; 132. ASH annual meeting, December 2018 (Poster)

25. LeBlanc R, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard E, **Bambace NM**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J. Bortezomib consolidation after front-line autologous and non-myeloablative allogeneic transplantation in high-risk and/or young myeloma patients is safe and associated with high depth of response: predictive value of minimal residual disease. ASH annual meeting, December 2018 (Poster)

26. Roy J, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard E, **Bambace N**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, LeBlanc R. Bortezomib consolidation after frontline auto-allogeneic transplant: low toxicity and frequent immunophenotypic complete responses in high-risk or young myeloma patients. American Society for Bone Marrow Transplantation (ASBMT) Annual Meeting, February 2018 (Poster)

27. Roy J, Claveau JS, Ahmad I, Landais S, **Bambace NM**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, LeBlanc R. Outcome of patients with multiple myeloma progression after frontline sequential autologous-allogeneic or autologous stem cell transplant only. American Society for Bone Marrow Transplantation (ASBMT) Annual Meeting, February 2018 (Poster)

28. Bouchard P, Brisebois-Boyer A, Charbonneau-Séguin N, Bonhomme V, Ahmad I, **Bambace NM**, Bernard L, Cohen S, Delisle JS, Kiss T, Sauvageau G, Roy DC, Roy J, Lachance S. Effectiveness of continuous infusion of methylprednisolone for prevention of antithymocyte globulin (ATG)infusion-related reactions in preparative regimens for allogeneic hematopoietic cell transplantation (HCT). American Society for Bone Marrow Transplantation (ASBMT) Annual Meeting, February 2018 (Poster)
29. Cohen S, Marinier A, Lachance S, Roy J, Delisle JS, Busque L, Roy DC, Ahmad I, **Bambace N**, Bernard L, Kiss T, Larochelle F, Caudrelier P, Landais S, Lemieux S, Zandstra P, Sauvageau G. The UM171 cord blood expansion trial: smaller, better HLA matched cords in short 7 day fedbatch cultures already provide clinical and cost benefits. 43rd Annual Meeting of the EBMT. April 2017 (Poster)
30. Boisjoly JA, Bouchard P, Cohen S, Ahmad I, **Bambace NM**, Bernard L, Delisle JS, Kiss T, Roy DC, Sauvageau G, Roy J, Lachance S. Impact of Carmustine (BCNU) substitution for Bendamustine in the conditioning regimen prior to autologous hematopoietic cell transplantation for the treatment of lymphoma. ASH annual meeting, December 2017 (Poster)
31. Richard LeBlanc, Imran Ahmad, Rafik Terra, Séverine Landais, Michael Sebag, Emilie Lemieux-Blanchard, **Nadia M. Bambace**, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas Kiss, Silvy Lachance, Denis-Claude Roy, Guy Sauvageau, Jean Roy; Bortezomib Consolidation after Nonmyeloablative Allogeneic Transplant Is Safe and Leads to a High Incidence of Immunophenotypic Complete Response in High-Risk or Young Myeloma Patients. *Blood* 2017; 130. ASH annual meeting, December 2017 (Poster)
32. Cohen S, Roy J, Lachance S, Marinier A, Roy DC, Delisle JS, Busque L, Caudrelier P, Larochelle F, Bouchard P, **Bambace NM**, Bernard L, Kiss T, Lemieux S, Zandstra P, Sauvageau G. Single UM171 Expanded cord blood is feasible, safe, and permits transplantation of better HLA matched cords with very low transplant related mortality. ASH annual meeting, December 2017 (Oral Presentation)
33. Tardif M, Ahmad I, **Bambace NM**, Bernard L, Busque L, Delise JS, Kiss T, Fleury I, Lachance S, Mollica L, Nkoue C, Roy DC, Roy J, Cohen S. Tandem autologous followed by nonmyeloablative allogeneic transplantation in relapsed high risk follicular lymphoma leads to excellent long term progression free survival after 8 years of follow-up. ASH annual meeting, December 2016 (Poster)
34. LeBlanc R, Ahmad I, Terra R, Landais S, Sebag S, Lemieux-Blanchard E, **Bambace N**, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J. Bortezomib consolidation after allogeneic nonmyeloablative transplantation leads to a high incidence of immunophenotypic complete response in young or high-risk multiple myeloma patients. ASH annual meeting, December 2016 (Poster)
35. Lemieux C, **Bambace NM**, Roy J, Cohen S, Ahmad I, Bernard L, Delisle JS, Kiss T, Lachance S. Evaluation of the impact of hematopoietic stem cell transplant on the quality of life of elderly patients treated for lymphoma. ASH annual meeting, December 2016 (Poster)
36. LeBlanc R, Ahmad I, Landais S, Terra R, **Bambace N**, Bernard L, Cohen S, Delisle JS, Gyger M, Kiss T, Lemieux-Blanchard É, Lachance S, Roy DC, Sauvageau G, Sebag M and Roy J. Bortezomib consolidation after allogeneic NMA transplantation to improve outcome in poor prognosis newly diagnosed MM patients: a preliminary safety report. Canadian Bone Marrow Transplant Group (CBMTG) meeting, December 2016 (Poster)
37. LeBlanc R, Ahmad I, Landais S, Terra R, **Bambace N**, Bernard L, Cohen S, Delisle JS, Gyger M, Kiss T, Lemieux-Blanchard É, Lachance S, Roy DC, Sauvageau G, Sebag M, Roy J. Bortezomib consolidation after allogeneic NMA transplantation to improve outcome in poor prognosis newly diagnosed MM patients: a preliminary safety report. American Society for Bone Marrow Transplantation (ASBMT). Annual Meeting, February 2015 (Poster)
38. Christopher Lemieux, Imran Ahmad, **Nadia M. Bambace**, Lea Bernard, Sandra Cohen, Jean-Sebastien Delisle, Thomas Kiss, Jean Roy, Silvy Lachance; Safety and Efficacy of Autologous Hematopoietic Cell

Transplantation for Elderly Patients with Lymphoma: Chemosensitive Disease Rather Than Age or Co-Morbidity Index Predicts Outcome. *Blood* 2015; 126 (23): 3171. ASH annual meeting, December 2015 (Poster)

39. Lemieux C, Ahmad I, **Bambace N**, Bernard L, Cohen S, Delisle JS, Kiss T, Roy J, Lachance S. Safety and efficacy of autologous hematopoietic cell transplantation for elderly patients with lymphoma: chemosensitive disease rather than age or co-morbidity index predicts outcome. American Society for Bone Marrow Transplantation (ASBMT). Annual Meeting, February 2015 (Poster)
40. Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle S, **Bambace N**, Bernard L, Roy J. Favorable long-term survival of patients with multiple myeloma using a frontline tandem approach with autologous and nonmyeloablative allogeneic transplantation. 15th International Myeloma Workshop, 2015 (Poster)
41. **Bambace NM**, Poirier L, Ahmad I, Bernard L, Cohen S, Kiss T, Sauvageau G, Roy J, Roy DC, Chagnon M, Lachance S. Nocardiosis in allogeneic hematopoietic stem cell transplant recipients: a matched case-control study of risk factors, clinical features and outcomes (ASBMT Tandem meetings in Salt-Lake City, UT. February 2013 (Poster)
42. Holmes CE, **Bambace NM**, Lewis P, Callas P, Cushman, M. Effectiveness of a short course of complex lymphedema therapy or graduated compression stocking therapy in the treatment of post-thrombotic syndrome (PTS): A randomized control trial. *Blood* (ASH Annual Meeting Abstracts), Nov 2010;116:1087. (Oral Presentation and Poster)
43. **Bambace NM**, Levis JE, Holmes CE. The Effect of P2Y-Mediated Activation of VEGF and Endostatin Release from Platelets. XXII International Society of Thrombosis and Hemostasis Congress 2009 in Boston, MA. July 13, 2009 (Oral Presentation)
44. Johnson S, Collins D, Amin A, **Bambace NM**, Grant BW. Non-pathologic rib fracture in a 36 year old healthy male: an unusual presentation of extranodal marginal zone lymphoma. National Research Poster Competition, American College of Physicians- American Society of Internal Medicine Annual Meeting; April 2009 (Poster)
45. **Bambace NM**. Acquired Hemophilia: an unusual paraneoplastic syndrome. National Research Poster Competition, American College of Physicians- American Society of Internal Medicine Annual Meeting; April 2007 (Poster)